AU Patent

AU2017359333B2 — Compositions and methods of modulating anti-tumor immunity

Assigned to Dana Farber Cancer Institute Inc · Expires 2024-03-21 · 2y expired

What this patent protects

The present invention provides methods of treating cancer by combination therapy with CDK4/6 inhibitors and immune checkpoint inhibition.

USPTO Abstract

The present invention provides methods of treating cancer by combination therapy with CDK4/6 inhibitors and immune checkpoint inhibition.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: AU2017359333B2
Jurisdiction: AU
Classification: —
Expires: 2024-03-21
Drug substance claim: No
Drug product claim: No
Assignee: Dana Farber Cancer Institute Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.